Poor
Mostly Unaligned
Patient Risk:
Moderate
Summary
Several statements about herbal supplements and specific symptom interpretations are not supported by the provided JYLAMVO prescribing information. The response also includes some claims that are phrased broadly (e.g., methotrexate being immunosuppressive, narrow safety margin) without label support, and it omits key label-required medication error and other safety details for supplement use.
Category Scores
Accurate Statements
Methotrexate may stress the liver.
Supported in part: JYLAMVO warns methotrexate can cause severe hepatotoxicity (Warnings 5.5).
Methotrexate may impact the liver and blood counts.
Supported in part: hepatotoxicity (Warnings 5.5) and myelosuppression/pancytopenia (Warnings 5.3).
Symptoms such as mouth sores or painful ulcers could indicate methotrexate toxicity or an adverse interaction.
Partially supported: common adverse reactions include ulcerative stomatitis (Adverse Reactions 6.1). The label does not discuss “adverse interaction” with supplements, but mouth sores are label-relevant to toxicity/adverse reactions.
Symptoms such as unusual bruising, bleeding, or frequent infections could indicate possible low blood counts.
Supported in part: myelosuppression with thrombocytopenia/leukopenia/neutropenia (Warnings 5.3). The label does not use these exact symptom examples.
Symptoms such as yellowing of the skin/eyes or dark urine could indicate possible liver issues.
Supported in part: hepatotoxicity can be severe (Warnings 5.5; Postmarketing hepatobiliary injury includes acute hepatitis/fibrosis/cirrhosis). The label does not specify these symptom descriptors.
Unsupported Statements
Methotrexate can interact with some herbal products.
JYLAMVO labeling provided does not mention herbal products or botanicals specifically.
Herbal supplements may affect how the body metabolizes methotrexate.
No label support for herbal products affecting metabolism.
Herbal supplements may affect how the liver handles methotrexate.
No label support for herbal products specifically affecting hepatic handling of methotrexate.
Herbal supplements may affect blood counts in patients taking methotrexate.
No label support linking herbal supplements to changes in blood counts.
The specific interactions between methotrexate and herbal supplements depend on the supplement’s ingredients.
No label support specific to herbal supplement ingredients.
The specific interactions between methotrexate and herbal supplements depend on the dose of methotrexate.
No label support for herbal-specific interaction dependence on methotrexate dose.
Herbal supplements should be treated as potentially unsafe until a clinician or pharmacist checks the exact product label.
No label support for “herbal supplement” guidance.
Clinicians recommend avoiding starting new supplements without approval when taking methotrexate.
No label support for this general clinician recommendation about supplements.
Products marketed for “liver support” may contain multiple botanicals and concentrated extracts.
No label support for content of marketed products or botanical compositions.
Products marketed for “immune boosting” may contain multiple botanicals and concentrated extracts.
No label support for content of marketed products.
Products marketed for “weight loss” may contain multiple botanicals and concentrated extracts.
No label support for content of marketed products.
Products marketed for “detox” may contain multiple botanicals and concentrated extracts.
No label support for content of marketed products.
Liver-stressing herbs or multi-ingredient “liver support” products raise higher concern with methotrexate.
No label support for “liver-stressing herbs” or multi-ingredient herbal products.
Supplements may worsen mouth ulcers in patients taking methotrexate.
While ulcerative stomatitis is listed, the label does not support supplements as a cause.
Supplements may worsen stomach irritation in patients taking methotrexate.
The label supports GI toxicity (Warnings 5.4) but does not tie it to supplements.
Supplements may worsen blood-cell suppression in patients taking methotrexate.
No label support linking supplements to worsening myelosuppression.
Immune-modulating herbs raise higher concern with methotrexate.
No label support for “immune-modulating herbs.”
Methotrexate is already immunosuppressive.
No explicit label support in provided sections.
The safest approach is to check the supplement’s exact ingredients and concentrations against the treatment plan.
No label support for this supplement-checking approach.
Symptoms such as severe nausea, vomiting, or diarrhea could indicate methotrexate toxicity or an adverse interaction.
The label supports GI toxicity (Warnings 5.4) but does not mention severe nausea/vomiting/diarrhea as such, nor “adverse interaction” with supplements.
Symptoms such as shortness of breath or new/worsening fatigue could indicate methotrexate toxicity or an adverse interaction.
Pulmonary toxicity is mentioned (Warnings 5.6) but the label does not provide these symptom examples, and does not link to supplement interactions.
Methotrexate has a narrow safety margin for many people.
No such statement in the provided label text.
Methotrexate can affect rapidly dividing cells.
The provided label mechanism describes inhibition of dihydrofolic acid reductase and sensitivity of actively proliferating tissues; the specific phrasing is not directly supported as written.
Herbal products can change drug levels.
No herbal-specific interaction statement in provided label text.
Herbal products can add overlapping toxicity with methotrexate.
No herbal-specific toxicity overlap guidance in provided label text.
Combining two things that both stress the liver can increase the risk of complications.
No label support for this general statement in the context of herbal supplements.
Folic acid (or folinic acid/leucovorin) is commonly taken by people on methotrexate as prescribed.
No folate supplementation guidance appears in the provided JYLAMVO prescribing information sections.
Folic acid or folinic acid/leucovorin reduces certain side effects of methotrexate.
No folate guidance appears in the provided label text.
Reducing side effects commonly includes reducing mouth sores.
No folate/side-effect reduction guidance in provided label text.
Reducing side effects commonly includes reducing GI toxicity.
No folate/side-effect reduction guidance in provided label text.
Whether folic acid (or folinic acid/leucovorin) should be taken and at what dose depends on the regimen.
No folate guidance appears in the provided label text.
Over-the-counter “herbal folate” products should not replace prescribed folate.
No label support for “herbal folate” or advice about OTC products.
Folic acid regimens should be discussed with a clinician.
No folate guidance appears in the provided label text.
Herbal supplements are not a substitute for methotrexate’s disease control in conditions like rheumatoid arthritis or psoriasis.
The label indicates indications for RA and severe psoriasis, but does not include claims about herbal supplements as substitutes.
Stopping methotrexate in favor of supplements is not recommended.
No label support provided for stopping methotrexate in favor of supplements.
Herbal supplements should not be relied on to control inflammation.
No label support for herbal supplements’ efficacy or lack thereof.
If a supplement was taken once without symptoms, emergency care is usually not needed.
No label support for this specific triage instruction.
A prescriber or pharmacist should assess the ingredient list and future risk after taking a supplement without symptoms.
No label support for this post-supplement assessment instruction.
If warning symptoms such as mouth sores, bleeding/bruising, fever/infection, severe GI symptoms, or jaundice occur, medical advice should be sought right away.
The label includes serious/fatal adverse reaction risks and warnings about severe outcomes, but it does not provide this symptom-to-action checklist wording.
Patients should tell their rheumatologist/dermatologist or prescribing clinician about every supplement while on methotrexate.
No label support for counseling about supplements or specific clinician types.
Patients should provide the supplement bottle or a photo of the supplement facts panel and ingredient list to allow interaction assessment.
No label support for this specific documentation/request.
Many interactions depend on the specific botanical and dose.
No label support for herbal/botanical interactions.
A pharmacist should screen the supplement for interactions with methotrexate.
No label support for pharmacist screening of supplements specifically.
Starting multiple new products at once should be avoided to identify what caused side effects.
No label support for this behavioral instruction.
Use caution with products that are not standardized or have ingredient changes between batches.
No label support for standardization/batch variability of herbal products.
Contradictions
Important Omissions
Dose administration safety warnings specific to medication errors (e.g., weekly vs daily errors; use of copackaged syringe; teaspoons not appropriate; methotrexate 2 mg/mL).
Importance:
High
Pregnancy-related contraindication and contraception counseling for females and males of reproductive potential.
Importance:
High
Label-supported serious adverse reactions to monitor/withhold or discontinue for (severe GI toxicity, hepatotoxicity, pulmonary toxicity, severe dermatologic reactions, severe renal toxicity, serious infections, neurotoxicity).
Importance:
Moderate
Label-supported adverse reactions and postmarketing immune/GI/hepatobiliary reactions (e.g., anaphylaxis, hemorrhagic enteritis, intestinal perforation, acute hepatitis/fibrosis/cirrhosis) rather than symptom-based supplement-focused guidance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response adds many supplement-related interaction and symptom-to-toxicity/triage statements without label support, which could mislead patients. It omits key JYLAMVO medication error counseling and pregnancy/contraception contraindication details.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Major portion of content concerns herbal supplement interactions and symptom checklists that are not supported by the provided JYLAMVO labeling, and several label-critical safety elements (medication error and pregnancy contraception guidance) are omitted.
Suggested Improvement
Restrict claims to what the provided JYLAMVO label supports (e.g., known adverse reactions/warnings and medication error and pregnancy contraindications). Remove or qualify herbal/botanical-specific interaction statements and avoid detailed symptom-to-action checklists unless they are present in the label.